RLAY Q3 2021 Earnings — Relay Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RLAYRelay Therapeutics, Inc.

$2B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$666,000

Gross Profit

-$43M-6529.9% margin

Operating Income

-$61M-9157.7% margin

Net Income

-$61M-9134.1% margin

EPS (Diluted)

$-0.66

QoQ Revenue Growth

-21.1%

Cash Flow

Operating Cash Flow

-$53M

Free Cash Flow

-$55M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$672M

Total Liabilities

$101M

Stockholders' Equity

$571M

Cash & Equivalents

$229M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$666,000	$0	—
Gross Profit	-$43M	$0	—
Operating Income	-$61M	-$37M	-66.6%
Net Income	-$61M	-$36M	-68.6%